The global zoster vaccine market is experiencing significant growth, driven by an aging population, increased awareness of shingles, and advancements in vaccine technology. Below is a comprehensive overview of the market's key aspects:
The global zoster vaccine market was valued at USD 4.2 billion in 2023, growing at a CAGR of 8.1% from 2024 to 2033 and expected to reach USD 9.1 billion by 2033.
🆕 Recent Developments
GSK's Shingrix: In April 2024, GlaxoSmithKline (GSK) announced results from the ZOSTER-049 trial, demonstrating that Shingrix provides protection against shingles for over 10 years in adults aged 50 and above.
Pfizer & BioNTech: In February 2023, Pfizer and BioNTech initiated a Phase 1/2 trial for an mRNA-based shingles vaccine, aiming to explore its safety and immunogenicity.
SK Bioscience's SKYZoster: SK Bioscience received approval for its shingles vaccine, SKYZoster, in Malaysia in January 2023, marking its second overseas approval after Thailand.
Browse for Full Report at @ https://www.thebrainyinsights.com/report/zoster-vaccine-market-14423
🚀 Market Drivers
Aging Population: The increasing global aging population is a primary driver, as individuals over 50 are at higher risk for shingles.
Increased Awareness: Public health campaigns and educational programs have significantly increased awareness of shingles risks, especially among older adults, leading to higher vaccination rates.
Government Initiatives: Inclusion of shingles vaccines in national immunization programs, such as in the UK and South Korea, has boosted market growth.
⚠️ Market Restraints
Vaccine Hesitancy: Despite the availability of effective vaccines, hesitancy due to misinformation and concerns about side effects remains a significant barrier.
High Costs: The high cost of vaccines, such as Shingrix, can limit access, particularly in low-income regions.
Limited Access: In certain regions, access to zoster vaccines is limited due to logistical challenges and inadequate healthcare infrastructure.
🌍 Regional Segmentation Analysis
North America: Dominates the market with a 42.3% revenue share in 2023, driven by high awareness, supportive healthcare policies, and strong public health advocacy.
Europe: Significant market presence, with countries like the UK achieving vaccination rates of approximately 60% through national immunization programs.
Asia-Pacific: Emerging as a promising market, with countries like Japan, China, and Australia recognizing the importance of vaccinating their aging populations against shingles.
🌱 Emerging Trends
Recombinant Vaccines: Recombinant vaccines, like Shingrix, are gaining popularity due to their high efficacy and longer-lasting protection compared to live attenuated vaccines.
mRNA Technology: Companies like Pfizer and BioNTech are exploring mRNA-based shingles vaccines, which could offer improved efficacy and safety profiles.
Global Expansion: Companies are expanding into emerging markets, recognizing the growth potential in regions with increasing healthcare awareness and infrastructure development.
🔧 Top Use Cases
Preventive Healthcare: Zoster vaccines are primarily used to prevent shingles and its complications, such as postherpetic neuralgia, especially in adults aged 50 and above.
Public Health Programs: Inclusion in national immunization schedules to reduce the burden of shingles on healthcare systems.
🧩 Major Challenges
Regulatory Hurdles: Navigating complex regulatory landscapes for vaccine approval can be time-consuming and costly.
Supply Chain Logistics: Ensuring efficient distribution and maintaining cold chain requirements are critical challenges, especially in regions with limited infrastructure.
💡 Attractive Opportunities
Product Innovation: Developing vaccines with enhanced efficacy, longer-lasting protection, and better safety profiles presents significant growth opportunities.
Emerging Markets: Expanding into emerging markets with growing healthcare infrastructure and increasing awareness about shingles can drive market growth.
Strategic Partnerships: Collaborations between pharmaceutical companies and healthcare organizations can enhance vaccine accessibility and awareness.
🏢 Key Market Players
Company Name Notable Activities
GlaxoSmithKline plc (GSK) Developer of Shingrix, a recombinant zoster vaccine with high efficacy.
Merck & Co., Inc. Manufacturer of Zostavax, a live attenuated zoster vaccine.
Pfizer Inc. Collaborating with BioNTech on an mRNA-based shingles vaccine.
SK Bioscience Producer of SKYZoster, expanding into international markets.
CanSinoBIO Engaged in vaccine development, including zoster vaccines.
Geneone Life Science Involved in the development of DNA-based vaccines, including for shingles.
Vaccitech Biotech company working on T-cell immunotherapies and vaccines.
Jiangsu Recbio Technology Co., Ltd Developing adjuvanted recombinant shingles vaccines.
Changchun BCHT Biotechnology Co. Engaged in the development and production of vaccines, including zoster vaccines.
Curevo Inc. Focused on developing next-generation vaccines, including for shingles.
The zoster vaccine market is poised for continued growth, with opportunities for innovation, expansion into emerging markets, and increased public awareness driving demand.
Market Introduction
Market Dynamics
Segment Analysis
Some of the Key Market Players